Opus GeneticsIRD +0.94%24 Net Margin % is -3,038.25% as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Opus Genetics ranks worse than 77.82% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Opus Genetics's Net Income for the
three
months ended in Mar. 2026 was $-65.54 Mil. Opus Genetics's Revenue for the
three
months ended in Mar. 2026 was $2.16 Mil. Therefore, Opus Genetics's net margin for the quarter that ended in Mar. 2026 was -3,038.25%.
The historical rank and industry rank for Opus Genetics's Net Margin % or its related term are showing as below:
IRD'
s Net Margin % Range Over the Past 10 Years
Min: -9625.3 Med: -349.33 Max: 44.89
Current: -892.36
IRD's Net Margin % is ranked worse than 77.82% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs IRD: -892.36
Opus Genetics (NAS:IRD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Opus Genetics Net Margin % Related Terms
Opus Genetics Net Margin % Historical Data
* Premium members only.
The historical data trend for Opus Genetics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Opus Genetics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (IRD) has a Net Margin % of -3,038.25% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #737 out of 947 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Opus Genetics' Net Margin % too high?
Opus Genetics' current Net Margin % is -3,038.25%. Based on the distribution chart, Opus Genetics ranks #737 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Net Margin % compare to IFRX and RGNX?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #737 out of 947 companies for Net Margin %. This places Opus Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Opus Genetics and its competitors. Opus Genetics's current Net Margin % is -3,038.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $3.74 — trading 910.8% above its estimated fair value. The current Net Margin % is -3,038.25%. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Opus Genetics (IRD), the current Net Margin % is -3,038.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $3.74 is trading 910.8% above its estimated GF Value™ of $0.37.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
Net Margin %: -3,038.25%
GF Value™: $0.37 vs. price of $3.74 (910.8% above fair value)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
